Dean's List: New Funding Awards
Dean's List:
New Funding Awards
Notable and novel scientific awards to celebrate.
October 2024New Federal Awards | |||
| Kale Bongers | Internal Medicine | NIH K08 5 years | The Role of the Gut Microbiome in Post-Sepsis Skeletal Muscle Atrophy |
| Andrean Burnett | Radiation Oncology | NIH R01 5 years | Inflammation and EGFR crosstalk in HNSCC Therapy |
| Qiang Zhang | Neurology | NIH R01 5 years | Glycolysis and rodent models of Alzheimer's disease |
| Other Awards | |||
| Alejandro Comellas Freymond | Internal Medicine | National Jewish Health | Genetic Epidemiology of COPD (COPD Gene) |
| David Dickens | Pediatrics | GlaxoSmithKline, Inc. | Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination with Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR) |
| Jeremy Greenlee | Neurosurgery | Northwestern University Feinberg School of Medicine | Neuronal and network mechanisms of electrocortical stimulation |
| Ali Jabbari | Dermatology | Almirall | Gene expression signatures and upstream drivers of collapse of hair follicle immune privilege |
| Douglas Laux | Internal Medicine | Ascendis Pharma A/S | TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 /, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) |
| Santiago Gutierrez Ortega (Contact PI) Edgar Samaniego (MPI) | Neurology | Patient-Centered Outcomes Research Institute | DIRECT study |
| Sneha Phadke | Internal Medicine | Boehringer Ingelheim Pharma GmbH & Co. | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) in combination with intravenous trastuzumab deruxtecan (T-DXd) or in combination with intravenous trastu |
September 2024New Federal Awards | |||
| Georgina Aldridge | Neurology | NIH RF1 3 years | Vulnerability of the ascending arousal network to alpha-synuclein pathology |
| Zuhair Ballas | Internal Medicine | NIH S10 1 year | Imaging Cytometer (Equipment for Flow Cytometry) |
| Ruth Chimenti - Contact PI Kathleen Sluka - MPI James Holmes - MPI | NIH R61 2 years | Development of diagnostic and prognostic ultrasound imaging biomarkers for plantar heel pain | |
| Daniel Cook | Internal Medicine | NIH K08 5 years | Inhibiting CD4+ Th2 development and function by CFTR activity |
| Camille Dunn-Johnson | Otolaryngology | NIH R01 5 years | The Effectiveness of Cochlear Implants in Real-World Settings for Mild Cognitive Impairment and Dementia in Older Adults with Age-Related Hearing Loss |
| John Engelhardt | Anatomy and Cell Biology | NIH N92 4 years | National Ferret Resource & Research Center on Lung Disease - Federal Contract |
| Alicia Gerke - Contact PI Alejandro Pezzulo - MPI | Internal Medicine | NIH R56 1 year | The Role of Residential Bioaerosol Exposure in Pulmonary Sarcoidosis |
| Matthew Hoffman | Otolaryngology | NIH R03 2 years | Characterizing the impact of presbyphonia on social interaction |
| Allison Momany | Pediatrics | NIH R00 3 years | Neonatal Stress in Very Preterm Infants: Longitudinal Effects on Epigenetics and Neurodevelopment |
| Christopher Petkov | Neurosurgery | NIH U01 5 years | Laminar Circuit Motifs for Working Memory and Language: From Cells to Systems |
| Alexandra Petrucci | Neuroscience & Pharmacology | NIH F32 2 years | Lesion extent and seizure propagation pathways across acute infection and chronic epilepsy in an infection induced mouse model |
| Andrea Weber | Psychiatry | US Dept of Health & Human Services 3 years | The Substance Use Disorder Training Expansion to Advance Multidisciplinary Services in Iowa (SUD-TEAMS-IA) |
| Aaron Scherer | Internal Medicine | US Dept of Health & Human Services, CDC 5 years | UI Advancing Research in Immunization Services Network Coordinating Center (Contact PI is in the College of Public Health and the award sits there as well) |
| Competitive Renewal | |||
| Stephanie Radke | OBGyn | Iowa Dept of Health & Human Services 6 years | Maternal Health Innovation |
| Other Awards | |||
| Chandrikha Chandrasekharan | Internal Medicine | AstraZeneca LP | Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01) |
| David Dickens | Pediatrics | Merck Sharp & Dohme LLC | Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors |
| Nabeel Hamzeh - Contact PI Karin Hoth - MPI | Internal Medicine | Ann Theodore Foundation | The Neurobiology of Cognitive Dysfunction in Patients with Sarcoidosis. |
| Mariia Kumskova | Internal Medicine | Hemostasis & Thrombosis Research Society | Mechanism of bleeding in Ehlers-Danlos syndrome |
| Lama Noureddine | Internal Medicine | F. Hoffmann-La Roche Ltd | RO7434656, an antisense inhibitor of complement factor B, in patients with primary IgA nephropathy at high risk of progression |
| Kittika Poonsombudlert | Internal Medicine | Incyte Corporation | A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms |
| Antonio Sanchez | Internal Medicine | 89bio, Inc. | Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ENLIGHTEN-Cirrhosis) |
| Mark Schultz | Pediatrics | University of Notre Dame | Developing mRNA therapeutics and biomarkers for GSD III |
| Adeyinka Taiwo | Internal Medicine | Stanford University | Taiwo K12 - Diabetes-Docs: Physician-Scientist Career Development Program from Stanford |
| Chen Tan | Internal Medicine | Eurofins Viracor, LLC | BK Virus In Renal Transplant |
| Ziying Yan | Anatomy and Cell Biology | University of Kansas Center for Research, Inc. | Development of novel approaches for gene editing therapies of cystic fibrosis |
| Hanna Zembrzuska | Internal Medicine | Novartis Pharmaceuticals Corporation | Rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN) |
August 2024New Federal Awards | |||
| Zuhair Ballas | Internal Medicine | NIH S10 1 year | Imaging Cytometer |
| James Byrne | Radiation Oncology | NIH DP2 3 years | Novel extremophile-inspired radioprotectants |
| Po Hien Ear | Surgery | DoD, CDMRP 2 years | Targeted approach of Nrf2 inhibition in neuroendocrine cancers |
| Jonah Elliff | Microbiology | NIH F30 4 years | Evaluating the impact of malaria on immunogenecity of the Ebola virus vaccine |
| Eric Hoffman | Radiology | NIH S10 6 years | NAEOTOM Alpha Photon-Counting CT Scanner |
| David Kaczka - Contact PI Emmanuel Akor - MPI Daniel Meggo - MPI | Anesthesia | NSF 1 year | I-Corps: Translation Potential of a Low-cost Mechanical Ventilator for Underserved Communities |
| Thomas Kehl-Fie | Microbiology | NIH R01 2 years | Leveraging host-imposed metal starvation to elucidate the molecular and environmental factors that dictate metal utilization by the iron/manganese superoxide dismutase superfamily |
| Filiz Korkmaz | Microbiology | NIH R00 3 years | Establishing Mechanisms of LOX-1 Dependent Immune Regulation During Pneumonia |
| Hongshuai Li | Orthopedic Surgery | NIH R01 5 years | Role of FGF21 in DMD |
| Katherine Mathews | Pediatrics | US Dept of Health and Human Services, CDC | Surveillance of Muscular Dystrophies Component A: Iowa MD STARnet Core Site |
| Wendy Maury | Microbiology | NIH UH2 2 years | Identifying placental tissue tropism and cellular mechanisms of Ebola Virus transmission from mother to fetus in pregnancy |
| Patrick McNamara | Pediatrics | NIH UG3 6 years | 1/2 Milrinone for Prevention of Post-Patent Ductus Arteriosus Closure Syndrome in Extremely Preterm Infants (MIDAS Trial) - CCC |
| Aaron Seaman | Internal Medicine | US Dept of Health and Human Services, CDC 5 years | University of Iowa Prevention Research Center for Rural Health |
| Jacob Simmering | Internal Medicine | NIH K01 5 years | Remote monitoring using commercially available activity trackers and computer vision provides a holistic, low-cost assessment of Parkinson's disease symptoms |
| Jan Wessel | Neurology | NIH R21 2 years | The TMS-evoked potential as a measure of cortical excitation and inhibition during cognitive processes |
| Competitive Renewal | |||
| David Stoltz | Internal Medicine | Cystic Fibrosis Foundation | Iowa Cystic Fibrosis Foundation Research & Development Program |
| Other Awards | |||
| Eric Hoffman - Contact PI Alejandro Comells Freymond, MPI | Radiology | University of California San Francisco | SubPopulations and InteRmediate Outcomes in COPD (SPIROMICS) III |
| Douglas Laux | Internal Medicine | GlaxoSmithKline, Inc. | Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
| Merck Sharp & Dohme LLC | Neoadjuvant and adjuvant V940 (mRNA-4157) in combination with pembrolizumab (MK- 3475) versus standard of care, and pembrolizumab monotherapy in participants with resectable locally advanced cutaneous squamous cell carcinoma | ||
| Katherine Mathews | Pediatrics | Larimar Therapeutics, Inc. | Jive: An Open-Label Extension Study to Assess the Long-term Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Subcutaneous CTI-1601 in Subjects with Friedreich's Ataxia |
| Peggy Nopoulos | Psychiatry | Anonymous - Domestic | Scanlan Scobell Psychedelic Research |
| John Rieth | Internal Medicine | Ascentage Pharma Group, Inc. | APG-115 as a monotherapy or in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors. |
| Antonio Sanchez | Internal Medicine | Boehringer Ingelheim Pharmaceuticals, Inc. | Multicenter, randomised, double-blind, placebo-controlled, 48-week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) |
| Jodi Tate | Psychiatry | The Molina Healthcare Charitable Foundation | Project ECHO: Iowa's IDD Complex Care Needs ECHO for Direct Care Professionals |
| Hanna Zembrzuska | Internal Medicine | Novartis Pharmaceuticals Corporation | Rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cutaneous systemic sclerosis |
July 2024New Federal Awards | |||
| Amy Conrad | Pediatrics | NIH R01 4 years | Speech Development and Brain Structure/Function in Infants with Isolated Oral Clefts: Relationship Anesthesia Exposure and Oxygenation |
| Huxing Cui | Neuroscience & Pharmacology | NIH R01 5 years | Uncovering the role of hypothalamic ciliary cAMP signaling in sex-specific control of metabolic homeostasis |
| Chad Grueter | Internal Medicine | NIH R01 5 years | Mediator kinase regulation of cardiac transcription |
| Priya Issuree | Internal Medicine | NIH R35 5 years | Connecting epigenetic programming of T cells with molecular traits of the immune system in health and disease |
| Bradley Jones | Microbiology | NIH R03 2 years | Influence of an E. coli hyperadherent probiotic on Salmonella intestinal colonization |
| Louis Kolling | Neuroscience & Pharmacology | NIH F32 1 year | Reversal of Tau Pathology to Rescue Serotonergic Function in Early Alzheimer's Disease |
| Balaji Manicassamy | Microbiology | NIH R01 5 years | Investigation of host glycan requirements for the transmission of influenza viruses at the human-animal interface |
| Paul McCray | Pedicatrics | NIH R03 1 year | Impact of ATP-binding cassette A3 (ABCA3) mutations on alveolar type 2 cell function and genetic complementation |
| Mark Schultz | Pediatrics | NIH R35 5 years | Regulation and Mechanisms of ER Proteostasis |
| Sam Stephens | Internal Medicine | NIH R01 3 years | Metabolic control of beta-cell secretory organelle function |
| Seth Tomchik | Neuroscience & Pharmacology | DoD, CDMRP 3 years | Mechanisms of Neuronal Dysregulation Underlying Behavioral Alterations in Neurofibromatosis Type 1 |
| Competitive Renewal | |||
| Steven Lentz - Contact PI Anil Chauhan - MPI | Internal Medicine | NIH T32 5 years | Program in Hematology: Molecular & Cell Biology Blood Cells |
| Matthew Pothoff | Neuroscience & Pharmacology | NIH R01 4 years | Regulation of Metabolism by FGF21 |
| Daniel Tranel - Contact PI Sheila Baker - MPI Gordon Buchanan - MPI | Neurology | NIH T32 5 years | Neuroscience Training Program |
| Other Awards | |||
| Umar Farooq | Internal Medicine | Janssen Research & Development, Inc. | A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
| Paul McCray | Pediatrics | Emily's Entourage | Enhanced Airway Transduction and Therapeutic Cargo Delivery with novel AAV Capsid Variants |
| Mohammed Milhem | Internal Medicine | Replimune, Inc. | A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician's Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen |
| Eric Mou | Internal Medicine | BeiGene USA | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Obinutuzumab in patients with previously untreated chronic Lymphocytic Leukemia |
| Christopher Strouse | Internal Medicine | Janssen Research & Development, Inc. | A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in Combination with Daratumumab SC (Tec-D) Following Induction with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants with Standard-risk Newly Diagnosed Multiple Myeloma |
| Yousef Zakharia | Internal Medicine | Kura Oncology | Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO 2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors |
| Merck & Company, Inc. | A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy | ||
June 2024New Federal Awards | |||
| Sarah Beattie | Pediatrics | NIH R21 2 years | HTS with Aspergillus fumigatus for novel, mold-active antifungals |
| Ruth Chimenti | Physical Therapy | DoD, CDMRP 4 years | Expanding and Accelerating Access to Care for Achilles Tendinopathy through Self-management Rehabilitation Strategies |
| Martine Dunnwald | Anatomy & Cell Biology | NSF 4 years | Formation and function of the periderm |
| Elissa Faro | Internal Medicine | NIH R01 5 years | Can an Evidence-Based Mental Health Intervention be Implemented into Preexisting Home Visiting Programs using Implementation Facilitation? |
| John Harty | Pathology | NIH R01 5 years | Brain T cell interactions in microbial experienced mice |
| NIH R21 2 years | Brain T cell interactions in microbial experienced mice | ||
| Christopher Petkov | Neurosurgery | NSF 4 years | Neural Mechanisms for Auditory Memory Sequencing and Prediction |
| Anjali Sharathkuman | Pediatrics | NIH R21 1.5 years | Epidemiology and Biosocial risk factors for adverse outcomes of COVID-19 in people with sickle cell disease : Analyses of national COVID surveillance registry |
| Daniel Tranel | Neurology | NIH T32 5 years | Understanding Health and Disease at the Behavioral-Biomedical Interface |
| Budd Tucker, Contact PI Robert Mullins, MPI | Ophthalmology | NIH R01 4 years | Sustained Treatment of Wet AMD |
| Jessica Tucker | Microbiology | NIH R21 2 years | Gammaherpesviruses induce transfer RNA cleavage |
| Other Awards | |||
| James Byrne | Radiation Oncology | Dr. Ralph and Marian Falk Medical Research Trust | Novel materials to improve management of hypoxic tumors |
| Margaret Byrne | Internal Medicine | Merck & Company, Inc. | Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer |
| Linda Cadaret | Internal Medicine | GB002, Inc. | PROSERA |
| Alejandro Comellas Freymond | Internal Medicine | Duke University | RECOVER-AUTONOMIC: A Platform Protocol for Evaluation of Interventions for Autonomic Dysfunction in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) |
| Marlan Hansen, Contact PI Matthew Howard, MPI Samuel Young, MPI | Otolaryngology | M34 Inc. | Recombinant AAV capsid library screening to identify clinically relevant capsid variants in humans |
| Markus Kuehn | Opthalmology | Boehringer Ingelheim GmbH | AMPK Activation for Neuroprotection in Glaucoma |
| Douglas Laux | Internal Medicine | GlaxoSmithKline LLC | Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck |
| Lama Noureddine | Internal Medicine | Amgen, Inc. | Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis |
| Tahaunty Pena | Internal Medicine | Sanofi US Services Inc. | Oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung tr |
| Michael Shy | Neurology | Elpida Therapeutics SPC | A Prospective Natural History and Outcome Meausre Discovery Study of Charcot-Marie-Tooth Disease, Type 4J |
| Ian Thornell | Internal Medicine | Cystic Fibrosis Foundation | Cellular contributions to HEMT |
| Praveen Vikas | Internal Medicine | Pfizer, Inc. | PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR BASED THERAPY |
| Michael Wendt | Internal Medicine | Novartis Pharmaceuticals Corporation | Impact of Hypoxia on Lipid Metabolism in Obesity-Driven Breast Cancer Progression |
| Hanna Zembrzuska | Internal Medicine | Novartis Pharmaceuticals Corporation | Intravenous secukinumab infusion in adults with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR). |
May 2024New Federal Awards | |||
| Barry London, Contact PI Bryan Allen, MPI | Internal Medicine | NIH U01 3 years | Sex-dependent Impairment of Nitric Oxide Signaling and Mitochondrial Metabolism in Radiation-Induced Cardio-Pulmonary Dysfunction |
| Vincent Magnotta, Contact PI Jacob Mathews, MPI | Radiology | NIH R01 5 years | High Resolution MRSI for Alzheimer's Disease and Related Dementias |
| Maria Spies | Biochemistry | NIH T32 5 years | Iowa Biotech-TP: Predoctoral Program in Biotechnology |
| Colette Galet | Emergency Medicine | DHHS, Administration on Aging 3 years | Empowering Communities to Deliver and Sustain Evidence-Based Falls Prevention Programs |
| Hua Sun | Pediatrics | NIH R01 5 years | Targeting dynein-mediated trafficking in diabetic podocytopathy |
| Rebecca Dodd | Internal Medicine | Dod, CDMRP 3 years | Targeted Therapy for MPNST Metastasis |
| Competitive Renewal | |||
| Vanessa Curtis, Contact PI Thomas Scholz, MPI | Pediatrics | Iowa DHHS 1 year | Pediatric Mental Health Care Access Program (PMHCAP) |
| Other Awards | |||
| Carol Johnson | Pediatrics | Iowa DHHS 5 years | Iowa Newborn Screening (NBS) Propel Project |
| Grerk Sutamtewagul | Internal Medicine | Kura Oncology 3 years | Venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia |
| Kura Oncology 3 years | Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia | ||
| Douglas Laux | Internal Medicine | Regeneron Pharmaceuticals, Inc. 3 years | REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with Cemiplimab in patients with advanced solid tumors. |
| David Bender | OBGyN | GOG Foundation 5 years | NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer |
| GOG Foundation 3 years | VB10.16 Alone or in Combination with Atezolizumab in Patients with HPV16-Positive, PD-L1-positive, Recurrent or Metastatic Cervical Cancer who are Refractory to Pembrolizumab with Chemotherapy with/without Bevacizumab | ||
| Sam Stephens | Internal Medicine | Juvenile Diabetes Research Foundation International 3 years | 201311107-FY24 SRA: Role of -cell Golgi dysfunction in Type 1 diabetes pathogenesis |
| Christopher Strouse | Internal Medicine | Janssen Research and Development, LLC 2.5 years | Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants with High-Risk Multiple Myeloma |
April 2024New Federal Awards | |||
| Jing Jiang | Pediatrics | NIH R01 5 years | Mapping a Causal Prefrontal Pathway for Amygdala Modulation Utilizing Invasive and Noninvasive Brain Stimulation and Recording Methods in Humans |
| Marco Hefti | Pathology | NIH R01 5 years | A non-canonical role for tau in early human brain development |
| Budd Tucker | Ophthalmology | NIH R21 2 years | Label-free microfluidic isolation of patient iPSC-derived photoreceptor cells |
| Steven Offer | Pathology | NIH R01 2 years | A precision medicine approach to improve prediction of severe toxicity in fluorouracil chemotherapy |
| Competitive Renewals | |||
| George Richerson | Neruology | NIH R01 5 years | Inhibition of central CO2 chemoreception by seizures: Effects on ventilation, cardiovascular control and postictal recovery of consciousness |
| Other Awards | |||
| Alejandro Comellas Freymond | Internal Medicine | KUMC 5 years | All of Us Research Program - Heartland Consortium |
| Erin Shriver | Ophthalmology | Immunovant Sciences, GmbH 5 years | Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED) |
| Yousef Zakharia | Internal Medicine | Astellas Pharma Global Development, Inc 3 years | Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED) |
| Hanna Zembrzuska | Internal Medicine | ImmPACT Bio USA, Inc. 3 years | IMPT-514 in participants with active, refractory lupus nephritis and systemic lupus erythematosus |
| David Bushnell | Radiology | RayzeBio, Inc. 5 years | RYZ101 in combination with carboplatin + etoposide + atezolizumab in subjects with somatostatin receptor expressing (SSTR+) extensive stage small cell lung cancer (ES-SCLC) |
| Christopher Strouse | Internal Medicine | Janssen Research & Development, Inc 5 years | JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma |
| Tracey Cho | Neurology | Sanofi US Services, Inc 5 years | Frexalimab (SAR441344) to Terifluomide (Aubagio) in Adult Participants with Relapsing Forms of Multiple Sclerosis |
| Sanofi US Services, Inc 5 years | Frexalimab (SAR441344) to Placebo in Adult Participants with Nonrelapsing Secondary Progressive Multiple Sclerosis | ||
| Katherine Mathews | Pediatrics | Avidity Biosciences, Inc 5 years | AOC 1044 Administered Intravenously to Healthy Adults |
| Val Sheffield | Pediatrics | CRISPR Therapeutics, Inc 2 years | MYOC gene editing for Myocilin Associated Glaucoma |
March 2024New Federal Awards | |||
| Sandra Blom | Internal Medicine | NIH F31 3 years | GRASP55 Regulates Pancreatic Beta-cell Golgi Structure and Function During Cytokine Stress |
| Songhai Chen, Contact PI Ronald Wiegel, MPI | Neuroscience & Pharmacology | NIH R01 5 years | Role of the CTLH E3 ubiquitin ligase in breast cancer progression |
| Carl Andrew Frank | Anatomy & Cell Biology | NIH R01 5 years | Synaptic defects caused by Mitochondrial Complex I dysfunction |
| Stephanie Gantz | Physiology | NIH R01 5 years | Regulation of monoamine neurons by delta glutamate receptors |
| Lyndsay Harshman | Pediatrics | DoD, CDMRP 2 years | Women's Health in Tuberous Sclerosis Complex: A Population Based Assessment of Morbidity to Inform Clinical Care |
| Miriam McDonough | Neuroscience & Pharmacology | NIH F31 3 years | Investigating the molecular mechanisms underlying aldosterone-mediated sodium appetite |
| Scott Moye-Rowley | Physiology | NIH R21 2 years | Novel mechanisms of azole resistance in clinical isolates of Candida glabrata |
| Krystal Parker | Psychiatry | NIH R21 2 years | Roles of Descending Forebrain Pathways to the Cerebellum in Behavioral Timing |
| Mark Schultz | Pediatrics | NIH R03 2 years | Investigating the importance of liver-specific glycans on NPC1 proteostasis |
| Hanna Stevens | Psychiatry | NIH R01 3 years | Adolescent Insecticide Exposure and ADHD Risk: Mechanisms of Immediate Effects and Ongoing Vulnerability |
| Stefan Strack | Neuroscience & Pharmacology | DoD, CDMRP 2 years | Identifying temporal and spatial origins and reversibility in mouse models of neurodevelopmental disorders with autism |
| Ajit Vikram | Internal Medicine | NIH R01 5 years | Glycopeptide vancomycin reshapes gut microbiota to mediate cardioprotective effects via microRNA-204 |
| Jason Wilken | Physical Therapy | DoD, CDMRP 2 years | The Effects of Heel Clearance on Foot Loading with Carbon Fiber Custom Dynamic Orthoses |
| Competitive Renewals | |||
| Julien Sebag | Physiology | NIH R01 4 years | Investigating the requirement of MRAP2 for ghrelin function |
| Maria Spies | Biochemistry | NIH R35 5 years | Assembly and Dynamics of Molecular Machines in Genome Maintenance |
| Other Awards | |||
| John Bernat | Pediatrics | Denali Therapeutics 5 years | DNL126 in pediatric participants with mucopolysaccharidosis type IIIA (Sanfilippo Syndrome Type A) |
| Marina Del Rios, Contact PI Kari Harland, MPI | Emergency Medicine | Robert Wood Johnson Foundation 2 years | Innovation and Measurement of Pre-emptive Action on Racial Justice and Health Equity Curriculum Teaching (IMPACT) |
| Mohammed Milhem | Internal Medicine | Polaris Pharmaceuticals, Inc. 5 years | Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial |
| Antonio Sanchez | Internal Medicine | GlaxoSmithKline, Inc. 3 years | GSK4532990 in Adults with pre-cirrhotic Non-Alcoholic Steatohepatitis (NASH) |
| Lane Strathearn | Pediatrics | EarliTec Diagnostics, Inc. 5 years | Dynamic Quantification of Social-Visual Engagement (DQSVE) in Autism Spectrum Disorder (ASD): Diagnosis and Assessment For Children Ages 31 - 84 Months. |
| Christopher Strouse | Internal Medicine | Juno Therapeutics, Inc. 4 years | BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma |
| Grerk Sutatewagul | Internal Medicine | Merk Sharp & Dohme, LLC 5 years | Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) |
| Tomohiro Tanaka | Internal Medicine | Takeda Development Center Americas, Inc. 5 years | Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis |
| Budd Tucker | Ophthalmology | Gilbert Famiy Foundation 3 years | Development of novel next generation model systems for study and treatment of NF1 |
| Yousef Zakharia | Internal Medicine | Arsenal Biosciences 3 years | AB-2100 in patients with recurrent advanced or metastatic clear-cell renal cell carcinoma. |
February 2024New Federal Awards | |||
| Michael Anderson, Contact PI Todd Scheetz, MPI John Fingert, MPI | Physiology, Ophthalmology | NIH R01 4 years | Foundational Biology of Glaucoma GWAS Loci |
| Denice Hodgson-Zingman, Contact PI Leonid Zingman, MPI | Internal Medicine | NIH R01 5 years | A New Pacing Approach for Cardiac Conditioning and Enhanced Cardioprotection |
| Emily Adelizzi | Anatomy & Cell Biology | NIH F31 3 years | Deciphering a tissue specific role for Arhgap29 during palatogenesis |
| Damian Krysan | Pediatrics | NIH R01 5 years | REgulation of Candida albicans Pathogenesis by Protein Kinase and Transccription Factor |
| Sarah Short | Internal Medicine | NIH K01 5 years | Antioxidant regulation of intestinal homeostasis and disease |
| Other Awards | |||
| Don Andrson | Orthopedic Surgery | Arthritis Foundation 2 years | Determining the traumatic origins of ankle OA and the time to joint degeneration |
| Tracey Cho | Neurology | Genetech, Inc. 5 years | Satralizumab in patients with anti-n-methyl D aspartic acid receptor (NMDAR) or anti-leucine rich glioma inactivated 1 (LGI1) |
| Prajwal Dhakal | Internal Medicine | Nerviano Medical Sciences, S.r.l. 3 years | A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML |
| Douglas Laux | Internal Medicine | Hoosier Cancer Research Network, Inc. 3 years | A Single Arm Phase II Study with Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination with Immunotherapy for Patients with Merkel Cell Cancer (HCRN MCC20-443; iPRRT Study) |
| Melinda Seering | Anesthesia | Haisco-USA Pharmaceuticals, Inc. 5 years | A Global Multicenter, Randomized, Double-blinded, Propofol controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HSK3486 Injectable Emulsion for Induction of General Anesthesia in Adults Undergoing Elective Surgery |
| Saima Sharif | Internal Medicine | PDD Investigator Services, LLC 3 years | A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer |
January 2024New Federal Awards: | |||
Patrick Sinn, Contact PI Paul McCray, MPI | Pediatrics | NIH R01 4 years | Adenine Base Edited Correction of Cystic Fibrosis Airways |
| Lane Strathearn | Pediatrics | NIH R01 4.5 years | Perinatal Experience and Epigenetic Change in Autism: Discovering Modifiable Pathways for Intervention |
| Michael Tomasson | Internal Medicine | US National Science Foundation 1 year | I-Corps: A Home-based Solution for Remote Lung Function Monitoring for Patients with Chronic Lung Disease |
| Other Awards: | |||
| Ted Abel | Neuroscience & Pharmacology | Eagles Autism Foundation 2 years | Characterizing the functional impact of mutations in Nr4a2-related Neurodevelopmental Syndrome |
| Huxing Cui | Novo Nordisk Pharmaceuticals, Inc | Novo Nordisk Pharmaceuticals, Inc 2 years | Neural basis of metabolic control by ciliary cAMP signaling |
| Alina Dumitrescu | Ophthalmology | Janssen Research & Development, Inc. 8 years | Global Patient Registry of Inherited Retinal Diseases |
| Rami El Abiad | Internal Medicine | Sanofi US Services Inc. 3 years | Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants with Eosinophilic Esophagitis (EoE) |
| Umar Farooq | Internal Medicine | Janssen Research & Development, Inc. 3 years | Global Patient Registry of Inherited Retinal Diseases |
| Mark Granner | Neurology | Neurona Therapeutics, Inc 4 years | A First-in-human (FIH) Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE) |
| Jon Houtman | Microbiology | Roy J. Carver Charitable Trust 1 year | State-of-the-art multicolor cellscape imaging system by canopy biosciences. |
| Asad Javed | Internal Medicine | IDEAYA Biosciences Inc. 5 years | IDE196 (Darovasertib) in combination with Crizotinib versus investigator's choice of treatment as a first-line therapy in HLA-A2 negative metastatic uveal melanoma (DAR-UM-2) |
| Douglas Laux | Internal Medicine | Regeneron Pharmaceuticals, Inc. 5 years | A multicenter, open-label phase 2 study of intratumoral vidutolimod (CMP-001) in combination with inravenous cemiplimabin subjects with selected types of advanced or metastatic cancer. |
| Paul McCray | Pediatrics | Cystic Fibrosis Foundation 2 years | 005651G223 Adenine Base Editing Repair of a CFTR Nonsense Mutation |
| Mohammed Milhem | Internal Medicine | Merck Sharp & Dohme LLC 8 years | Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma |
| Dawn Quelle, Contact PI Rebecca Dodd, MPI | Neuroscience & Pharmacology, Internal Medicine | Gilbert Family Foundation 3 years | Improving Immunotherapy in MPNSTs |
| Ziying Yan | Anatomy & Cell Biology | Cystic Fibrosis Foundation 2 years | Developing Basal Cell Tropic Human Bocavirus for Applications in Airway Gene Editing |
| Yousef Zakharia | Internal Medicine | Bristol-Myers Squibb Company 5 years | A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors |